Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Obstetricia y Ginecología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
INTERVENTIONAL
Inicio: 11 de jun de 2018
ID: NCT03517449
Completado
Fase 3
ClinicalTrials.gov
Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd
INTERVENTIONAL
Inicio: 1 de feb de 2002
ID: NCT00191152
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
INTERVENTIONAL
Inicio: 18 de oct de 2021
ID: NCT05104866
Desconocido
ClinicalTrials.gov
Oncoliq: Test for Early Breast Cancer Detection.
OBSERVATIONAL
Inicio: 1 de sept de 2021
ID: NCT04906330
Completado
ClinicalTrials.gov
Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment
OBSERVATIONAL
Inicio: 23 de dic de 2014
ID: NCT02326857
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)
INTERVENTIONAL
Inicio: 4 de dic de 2020
ID: NCT04622319
Completado
Fase 3
ClinicalTrials.gov
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
INTERVENTIONAL
Inicio: 29 de mar de 2013
ID: NCT01808573
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer
INTERVENTIONAL
Inicio: 1 de ago de 2006
ID: NCT00374322
Completado
Fase 3
ClinicalTrials.gov
A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women
INTERVENTIONAL
Inicio: 1 de ene de 2009
ID: NCT00808132
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
INTERVENTIONAL
Inicio: 9 de abr de 2025
ID: NCT06824467
Activo, no recluta
Fase 3
ClinicalTrials.gov
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
INTERVENTIONAL
Inicio: 8 de dic de 2022
ID: NCT05501886
Terminado
Fase 3
ClinicalTrials.gov
Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated
INTERVENTIONAL
Inicio: 1 de nov de 2006
ID: NCT00373113
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor
INTERVENTIONAL
Inicio: 16 de abr de 2020
ID: NCT04305496
Completado
ClinicalTrials.gov
Trial of the Use of Antenatal Corticosteroids in Developing Countries
INTERVENTIONAL
Inicio: 1 de oct de 2011
ID: NCT01084096
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy.
INTERVENTIONAL
Inicio: 17 de oct de 2012
ID: NCT01602380
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
INTERVENTIONAL
Inicio: 29 de jun de 2022
ID: NCT05257408
Terminado
Fase 2
ClinicalTrials.gov
An Open Label Randomized Phase 2 Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies
INTERVENTIONAL
Inicio: 22 de oct de 2019
ID: NCT04059484
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
INTERVENTIONAL
Inicio: 22 de dic de 2025
ID: NCT07174336
Completado
ClinicalTrials.gov
Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW
OBSERVATIONAL
Inicio: 1 de oct de 2006
ID: NCT00418236
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
INTERVENTIONAL
Inicio: 1 de oct de 2011
ID: NCT01437566
Anterior
1
...
12
13
14
...
434
Siguiente
Filtros